Anti-drug antibodies in the current management of cancer

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Monoclonal antibodies (mAbs) are key in oncology, used as targeted therapies and immune checkpoint inhibitors.
• Anti-drug antibodies (ADAs) can arise, affecting mAb pharmacokinetics, pharmacodynamics, efficacy, and safety, leading to infusion reactions.
• Factors influencing ADA development include host genetics, immune status, comorbidities, medications, and mAb characteristics.

Purpose of the Study:

• To review current discussions surrounding anti-drug antibodies (ADAs) in oncology.
• To highlight the implications of ADA detection for cancer patient treatment strategies.
• To explore strategies for reducing mAb immunogenicity and managing ADA-related issues.

Main Methods:

• Review of existing literature on ADAs in oncology.
• Discussion of ADA detection methods, primarily ELISA-type assays.
• Analysis of factors contributing to ADA development and strategies to mitigate them.

Main Results:

• ADAs can significantly alter the clinical profile of monoclonal antibody therapies.
• ADA analysis, though not routine, has critical implications for therapeutic adjustments in cancer care.
• Published studies on ADAs related to targeted therapies and immune checkpoint inhibitors are increasing.

Conclusions:

• ADA detection and management are vital for optimizing cancer patient outcomes with mAb therapies.
• Strategies to reduce mAb immunogenicity, such as altered dosing or immunosuppression, are being explored.
• Measuring active drug concentration is also considered for guiding administration schedules in the context of ADAs.